Tazomeline

Tazomeline
Clinical data
Other names	LY-287,041; LY-287041; LY287041; 3-Hexylthio-TZTP
ATC code	None;
Identifiers
	IUPAC name 5-[4-(hexylsulfanyl)-1,2,5-thiadiazol-3-yl]-1-methyl-1,2,3,6-tetrahydropyridine;
CAS Number	131987-54-7;
PubChem CID	131460;
ChemSpider	116193;
UNII	QDP6S14W5W;
ChEMBL	ChEMBL131819;
CompTox Dashboard (EPA)	DTXSID80157288 ;
Chemical and physical data
Formula	C14H23N3S2
Molar mass	297.48 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES n2snc(/C1=C/CCN(C)C1)c2SCCCCCC;

Tazomeline (LY-287,041) is a drug which acts as a non-selective muscarinic acetylcholine receptor agonist.^[1]^[2] It was in clinical trials for the treatment of cognitive dysfunction such as that seen in Alzheimer's disease and schizophrenia, but development was apparently scrapped for unknown reasons.^[1]^[2]^[3] Another of the patented uses is for the treatment of "severe painful conditions".

References

^ ^a ^b Langmead CJ, Watson J, Reavill C (February 2008). "Muscarinic acetylcholine receptors as CNS drug targets". Pharmacology & Therapeutics. 117 (2): 232–43. doi:10.1016/j.pharmthera.2007.09.009. PMID 18082893.
^ ^a ^b Amos D Korczyn (October 2000). "Muscarinic M1 Agonists in the Treatment of Alzheimer's Disease". Expert Opinion on Investigational Drugs. 9 (10): 2259–2267(9). doi:10.1517/13543784.9.10.2259. PMID 11060805. S2CID 32214700.
^ Mashkovskii MD, Glushkov RG (April 2001). "Drugs for the Treatment of Alzheimer's Disease". Pharmaceutical Chemistry Journal. 35 (4): 179–182. doi:10.1023/A:1010474325601. S2CID 39866378.